Geode Capital Management LLC Has $5.90 Million Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Geode Capital Management LLC reduced its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 20.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 901,262 shares of the company's stock after selling 237,861 shares during the quarter. Geode Capital Management LLC owned approximately 1.41% of Larimar Therapeutics worth $5,904,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in Larimar Therapeutics by 27.2% in the third quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company's stock valued at $36,379,000 after acquiring an additional 1,189,467 shares during the period. Driehaus Capital Management LLC lifted its holdings in shares of Larimar Therapeutics by 20.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,314,106 shares of the company's stock worth $9,527,000 after purchasing an additional 225,879 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Larimar Therapeutics by 30.2% in the 2nd quarter. Millennium Management LLC now owns 1,018,135 shares of the company's stock worth $7,381,000 after purchasing an additional 235,865 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Larimar Therapeutics by 37.7% during the 2nd quarter. Point72 Asset Management L.P. now owns 603,581 shares of the company's stock valued at $4,376,000 after purchasing an additional 165,181 shares during the period. Finally, Sphera Funds Management LTD. grew its stake in Larimar Therapeutics by 32.6% during the 3rd quarter. Sphera Funds Management LTD. now owns 414,478 shares of the company's stock worth $2,715,000 after buying an additional 102,009 shares during the last quarter. Institutional investors and hedge funds own 91.92% of the company's stock.

Analyst Upgrades and Downgrades

LRMR has been the subject of several analyst reports. William Blair reissued an "outperform" rating on shares of Larimar Therapeutics in a report on Tuesday, November 19th. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Larimar Therapeutics in a research note on Monday, December 16th. Wedbush assumed coverage on shares of Larimar Therapeutics in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $22.00 target price for the company. Finally, Oppenheimer assumed coverage on Larimar Therapeutics in a report on Wednesday, October 16th. They set an "outperform" rating and a $26.00 price target on the stock. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $20.43.

Larimar Therapeutics Stock Performance

Shares of LRMR stock traded up $0.17 during mid-day trading on Friday, hitting $4.18. 671,800 shares of the stock traded hands, compared to its average volume of 640,650. Larimar Therapeutics, Inc. has a twelve month low of $3.01 and a twelve month high of $13.68. The company's 50-day simple moving average is $6.17 and its 200-day simple moving average is $7.23. The firm has a market cap of $266.71 million, a price-to-earnings ratio of -3.63 and a beta of 0.86.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.13. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. Analysts forecast that Larimar Therapeutics, Inc. will post -1.16 earnings per share for the current year.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.